Results 21 to 30 of about 4,142 (135)

Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Background Postinflammatory hyperpigmentation (PIH) is the most common adverse effect following laser treatments, yet the relative efficacy of proposed prophylactic measures remains uncertain. Objectives To compare the effectiveness of available interventions for preventing laser‐induced PIH in randomized controlled trials (RCTs).
Supisara Wongdama, Sasitorn Yenyuwadee, Jayne Bernadeth Li, Surasak Saokaew, Sukrit Kanchanasurakit, Woraphong Manuskiatti   +5 more
wiley   +1 more source

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension

Indian Journal of Ophthalmology, 2014
Aims: The aim was to compare efficacy and cost-effectiveness of bimatoprost 0.03% and brimonidine 0.2% in primary open-angle glaucoma (POAG)/ocular hypertension (OHT). Settings and Design: Open, randomized, cross-over, comparative study.
Navreet Kaur Natt, A Gupta, G Singh, T Singh   +3 more
doaj   +1 more source

An Attempt to Establish the Consensus Regarding the Diagnosis, Classification, and Treatment of Rosacea in Japan Using a Modified Delphi Method: The Japan Rosacea Consensus

The Journal of Dermatology, EarlyView.
ABSTRACT In Japan, rosacea has attracted increasing interest. However, because rosacea had been thought to be relatively rare in Japan, the perception of this disease varies among dermatologists. To address these challenges, this study developed a consensus regarding the diagnosis, classification, and treatment of rosacea using a modified Delphi method
Kenshi Yamasaki, Nobukazu Hayashi, Hiroaki Hayashi, Yasuko Fukuya, Yuki Horiuchi, Miwa Kobayashi, Yoshimasa Nobeyama, Jun Omatsu, Kanako Tsunoda, Yoshiki Miyachi   +9 more
wiley   +1 more source

Brimonidine-Soluplus Nanomicelles: Preparation and in-vitro evaluation

Iraqi Journal of Pharmaceutical Sciences
Brimonidine is an active pharmaceutical ingredient used to treat glaucoma as a topical eye drop. Ophthalmic topical preparations are associated with low ocular bioavailability due to several physiological and analytical barriers.
Noor Al wiswasi, Fatima J. Al-Gawahri
doaj   +1 more source

Respiratuvar depression after accidental nasal ingestion of brimonidine eye drops in infant

Turkish Journal of Emergency Medicine, 2016
Objectives: Brimonidine tartrate is an alpha-2 agonist used for glaucoma treatment. It can lead to serious poisoning symptoms when misused by children.
Ali Gunes, Hasan Balik, Servet Yel, Halil Kocamaz, Mehmet Bosnak   +4 more
doaj   +1 more source

Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial

Scientific Reports, 2023
This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular ...
Ko Eun Kim, Chang Kyu Lee, Jonghoon Shin, Yuri Kim, Seungsoo Rho   +4 more
doaj   +1 more source

Congenital aniridia: European COST action ANIRIDIA‐NET guidelines for diagnosis, management and care

Acta Ophthalmologica, EarlyView.
Abstract Congenital aniridia is a rare ocular disorder affecting the majority of eye structures and can be associated with systemic manifestations. The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign. Other ocular comorbidities are associated
Davide Romano, Vito Romano, Alejandra Daruich, Giulio Ferrari, Matthieu Robert, Francesco Semeraro, Neil Lagali, Dominique Bremond‐Gignac, the ANIRIDIA‐NET Clinical Guidelines Working Group, Miriam Barbany, Claus Cursiefen, Stefano Ferrari, Francisco Figueiredo, Christina Grupcheva, Jesper Hjortdal, Elke Kreps, Erlend Landsend, Laura Mauring, Hilde Pedersen, Nora Szentmáry, Bogumil Wowra, the Aniridia‐Europa and Geniris Working Group, Sophie Valleix, Juan Álvarez de Toledo, James Lauderdale, Tor Paaske Utheim, Paolo Rama   +26 more
wiley   +1 more source

Brimonidine-associated uveitis – a descriptive case series

BMC Ophthalmology, 2020
Background Anterior uveitis secondary to topical brimonidine administration is rare and not well-defined. In glaucoma patients using brimonidine, one must consider this phenomenon to avoid mis-diagnosis and over-treatment with topical steroids which in ...
Susanne Hopf, Karl Mercieca, Norbert Pfeiffer, Verena Prokosch-Willing   +3 more
doaj   +1 more source

Impact of mono‐ or multitherapy on ocular surface health and quality of life after 5 years of follow‐up in the Glaucoma Intensive Treatment Study (GITS)

Acta Ophthalmologica, EarlyView.
Abstract Aim To evaluate the impact of initial mono‐ versus multitherapy on the ocular surface and related quality of life after 5 years follow‐up in the Glaucoma Intensive Treatment Study (GITS). Method The study included patients with primary open‐angle glaucoma and pseudoexfoliation glaucoma who completed 5‐year follow‐up in GITS.
Gauti Jóhannesson, Christina Lindén, Johan Aspberg, Sabina Andersson‐Geimer, Anders Heijl, Boel Bengtsson, Dorothea Peters   +6 more
wiley   +1 more source

A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model.

PLoS ONE
Glaucoma is a multifactorial optic neuropathy that primarily affecting retinal ganglion cells (RGC). Brimonidine is an intraocular pressure-lowering drug with reported neuroprotective properties. This study aimed to compare the neuroprotective effects of
Ruta Maciulaitiene, Giedrius Kalesnykas, Dainius Haroldas Pauza, Ingrida Januleviciene   +3 more
doaj   +1 more source